Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (version 3: revised may 20th, 2024)

Use of Gadolinium-Based Contrast Agents (GBCAs), a joint committee of the Japan Radiological Society and the Japanese Society of Nephrology, first announced guidelines for the use of GBCAs on July 25th, 2008 and revised them on September 2nd, 2009.Nephrogenic systemic fibrosis (NSF) is a disease characterized by swelling, hardening, and pain of the skin after exposure to GBCAs.Disease progression can lead to limb contractures, severely limiting physical activity.There is currently no known cure, and there have been reports of death due to complications from NSF. Taking into consideration new knowledge acquired since the previous revision, the Joint Committee has revised the guidelines as follows: